BioCentury
ARTICLE | Clinical News

GLP1-PEG: Phase Ib started

March 30, 2009 7:00 AM UTC

Eli Lilly began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate 14 mg of subcutaneous LY2428757 given once weekly in combination with 2 or 3 mg subcutaneous TT-223, a gastrin analo...